[Perioperative management for nephrectomy in a long-term hemodialysis patient with anticoagulants for coronary stent].
A 53-year old man on long-term hemodialysis (HD) with anticoagulant therapy was scheduled for nephrectomy due to renal cell carcinoma. Two months before surgery, a coronary stent had been placed due to right coronary artery disease. One week before surgery, percutaneous transmural coronary angioplasty (PTCA) was performed for unstable angina. Aggressive oral antiplatelet therapy (aspirin and ticlopidine) was absolutely required to maintain patency. Following withdrawal of the antiplatelets, unfractionated heparin (UFH) was titrated to an activated partial thromboplastin time (APTT) of 1.5 times greater than the control value. Maintenance UFH (800 U.h-1) was continued until the time of arrival in the operation room (activated clotting time (ACT) was 166 seconds). One hour after arrival, reduced dose of UFH (200 U.h-1) was reinfused, and ACT was 121 140 seconds. Hemodynamic change was minimized using balanced general anesthesia (nitrous oxide-isoflurane, fentanyl, midazolam and vecuronium) accompanied by nitroglycerin and diltiazem. There was no ischemic change on ECG or transesophageal echocardiography. Following surgery, the UFH dose was augmented (400 U.h-1), and the maintenance dose was attained 11 hours after surgery. HD on the second postoperative day was performed uneventfully. This hemodynamic stability might be come from the no water removal. Fourteen days after surgery, the patient was discharged without hemorrhagic complications or clinical ischemic events. We conclude that perioperative UFH infusion is not contraindicated for dialysis patient if strict ACT control is maintained.
Tabuchi
Y
Y
Department of Anesthesia, Nagahama City Hospital.
Nosaka
S
S
Amakata
Y
Y
Takamitsu
Y
Y
Shibata
N
N
D000925:Anticoagulants / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000601:surgery / Q000628:therapy; D003327:Coronary Disease / Q000628:therapy; D003331:Coronary Vessels; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D006435:Renal Dialysis; D015607:Stents
D000925:Anticoagulants; D006493:Heparin